Clinical Trials Logo

Clinical Trial Summary

This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).


Clinical Trial Description

The phase I dose-escalation pilot study is intended as an initial safety assessment to establish the MTD prior to the phase II randomized, double-blinded, placebo-controlled study. An estimated eighteen (18) patients in phase I who are scheduled to undergo cardiac catheterization and have met all inclusion/exclusion criteria will be enrolled. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05068674
Study type Interventional
Source Stanford University
Contact
Status Not yet recruiting
Phase Phase 1
Start date January 2022
Completion date October 2025

See also
  Status Clinical Trial Phase
Withdrawn NCT02503280 - The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial. Phase 1/Phase 2
Completed NCT02013674 - The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study) Phase 2